Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2-GDNF gene therapy in Parkinson's disease
NCT04167540Phase 1Active, not recruiting
- Sponsor
- Brain Neurotherapy Bio
- Start
- Apr 2020
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMT-140 in Parkinson's disease (PD) (2 arms), sponsored by Brain Neurotherapy Bio. Primary endpoint: Treatment-Emergent Adverse Events at 5 years. Started Apr 2020; status: active, not recruiting.
02
Drugs
AMT-140
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04167540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167540.